CytoSorbents Corp (CTSO)-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8014369)
◆英語タイトル:CytoSorbents Corp (CTSO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014369
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:42
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
CytoSorbents Corp (CytoSorbents), formerly MedaSorb Technologies Corp, is a critical care immunotherapy company that specializes in the development of blood purification products. Its flagship product, CytoSorb is an extracorporeal cytokine adsorber that is designed to control extreme systemic inflammation in seriously ill patients by reducing excessive cytokines and bacterial toxins. CytoSorb is also being administered during and after cardiac surgery to prevent post-operative complications such as multiple organ failure. The company offers VetResQ, a blood purification adsorber, to help treat excessive inflammation and toxic injury in animals. The company offers its products through a network of distributors across Europe, the Middle East and Asia Pacific. CytoSorbents is headquartered in Monmouth Junction, New Jersey, the US.

CytoSorbents Corp (CTSO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
CytoSorbents Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
CytoSorbents Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
CytoSorbents Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
CytoSorbents Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
CytoSorbents Corp, Medical Devices Deals, 2011 to YTD 2017 9
CytoSorbents Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
CytoSorbents Corp, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
CytoSorbents Enters into Distribution Agreement with Fresenius Medical Care for CytoSorb Therapy 11
CytoSorbents Extends Co-Marketing Agreement with Biocon for CytoSorb 12
Biocon Enters Into Co-Marketing Agreement With CytoSorbents For CytoSorb 13
Equity Offering 15
CytoSorbents Completes Private Placement Of Units For US$10.2 Million 15
CytoSorbents Corp – Key Competitors 16
CytoSorbents Corp – Key Employees 17
CytoSorbents Corp – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Recent Developments 19
Strategy And Business Planning 19
May 06, 2016: CytoSorbents Establishes Swiss Subsidiary 19
Financial Announcements 20
Nov 09, 2017: CytoSorbents Continues Strong Trajectory of Growth in the Third Quarter 2017 20
Aug 07, 2017: CytoSorbents Reports Record Quarterly Total Revenue and Product Sales in the Second Quarter 2017 25
May 08, 2017: CytoSorbents Reports First Quarter 2017 Financial Results 29
Mar 03, 2017: CytoSorbents Reports Record Quarterly and Full-Year 2016 Revenue 30
Jan 10, 2017: CytoSorbents Pre-announces Q4 2016 and Full-Year 2016 Results 31
Nov 07, 2016: CytoSorb Q3 2016 Sales Reach Record $2.14M, Doubling From a Year Ago 32
Aug 09, 2016: CytoSorbents Achieves Fourth Consecutive Quarter of Record CytoSorb Sales 33
May 09, 2016: CytoSorbents Continues Strong Growth in Q1 2016 34
Mar 09, 2016: CytoSorbents Reports Record Quarterly and Full-Year 2015 Revenue 37
Corporate Communications 38
May 30, 2017: Dr. Eric G. Mortensen, M.D., Ph.D., Clinical Trial Veteran, Joins CytoSorbents as Chief Medical Officer 38
Government and Public Interest 39
Nov 01, 2017: CytoSorbents Awarded Approximately $1.0 Million in Phase II SBIR Funding to Optimize New Treatment Approaches for Severe Hyperkalemia 39
Aug 14, 2017: CytoSorbents Awarded $719,000 Grant To Acutely Stabilize Severe Burn Patients 40
Aug 08, 2016: CytoSorbents Awarded $650,000 in SBIR Grant Contracts to Continue Development of Novel Hemocompatible Potassium Binding Polymers 41
Appendix 42
Methodology 42
About GlobalData 42
Contact Us 42
Disclaimer 42

List of Tables
CytoSorbents Corp, Pharmaceuticals & Healthcare, Key Facts, 2016 2
CytoSorbents Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
CytoSorbents Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
CytoSorbents Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
CytoSorbents Corp, Deals By Therapy Area, 2011 to YTD 2017 8
CytoSorbents Corp, Medical Devices Deals, 2011 to YTD 2017 9
CytoSorbents Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
CytoSorbents Enters into Distribution Agreement with Fresenius Medical Care for CytoSorb Therapy 11
CytoSorbents Extends Co-Marketing Agreement with Biocon for CytoSorb 12
Biocon Enters Into Co-Marketing Agreement With CytoSorbents For CytoSorb 13
CytoSorbents Completes Private Placement Of Units For US$10.2 Million 15
CytoSorbents Corp, Key Competitors 16
CytoSorbents Corp, Key Employees 17
CytoSorbents Corp, Subsidiaries 18

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ CytoSorbents Corp (CTSO)-製薬・医療分野:企業M&A・提携分析(CytoSorbents Corp (CTSO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆